Effect of pravastatin on fatty acid profile of low density lipoprotein in patients with hypercholesterolemia

C. Y. Hong; S. J. Lin; M. S. Chang; B. N. Chiang; P. M. Shen; M. S. Shiao

doi:10.1016/0952-3278(93)90104-5

Effect of pravastatin on fatty acid profile of low density lipoprotein in patients with hypercholesterolemia

C. Y. Hong^*, S. J. Lin, M. S. Chang, B. N. Chiang, P. M. Shen, M. S. Shiao

^*Corresponding author for this work

Research output: Contribution to journal › Journal Article › peer-review

3 Scopus citations

Abstract

We gave pravastatin, an HMG-CoA reductase inhibitor, to 21 hypercholesterolemic patients for 12 weeks after they had been on dietary therapy for 12 weeks. In addition to inducing a significant reduction of total cholesterol and LDL-cholesterol, pravastatin significantly decreased the proportion of linoleic acid (18:2) and increased that of saturated (FA) (16:0 and 18:0) in the cholesterol ester of LDL. Linoleic acid was also reduced in the triglyceride of LDL. Besides, monounsaturated FA (16:1 and 18:1) were increased in the cholesterol ester, triglyceride and phospholipid of LDL, but the changes in monounsaturated FA were not statistically significant. The effect of pravastatin on the FA profile of LDL was similar to that of fibric acid derivatives. The mechanism as well as the clinical implication of these changes await further investigation.

Original language	English
Pages (from-to)	155-158
Number of pages	4
Journal	Prostaglandins, Leukotrienes and Essential Fatty Acids
Volume	48
Issue number	2
DOIs	https://doi.org/10.1016/0952-3278(93)90104-5
State	Published - 02 1993
Externally published	Yes

Access to Document

10.1016/0952-3278(93)90104-5

Cite this

@article{8b4a2db7bc0c4a778e664e65241218d3,

title = "Effect of pravastatin on fatty acid profile of low density lipoprotein in patients with hypercholesterolemia",

abstract = "We gave pravastatin, an HMG-CoA reductase inhibitor, to 21 hypercholesterolemic patients for 12 weeks after they had been on dietary therapy for 12 weeks. In addition to inducing a significant reduction of total cholesterol and LDL-cholesterol, pravastatin significantly decreased the proportion of linoleic acid (18:2) and increased that of saturated (FA) (16:0 and 18:0) in the cholesterol ester of LDL. Linoleic acid was also reduced in the triglyceride of LDL. Besides, monounsaturated FA (16:1 and 18:1) were increased in the cholesterol ester, triglyceride and phospholipid of LDL, but the changes in monounsaturated FA were not statistically significant. The effect of pravastatin on the FA profile of LDL was similar to that of fibric acid derivatives. The mechanism as well as the clinical implication of these changes await further investigation.",

author = "Hong, \{C. Y.\} and Lin, \{S. J.\} and Chang, \{M. S.\} and Chiang, \{B. N.\} and Shen, \{P. M.\} and Shiao, \{M. S.\}",

year = "1993",

month = feb,

doi = "10.1016/0952-3278(93)90104-5",

language = "英语",

volume = "48",

pages = "155--158",

journal = "Prostaglandins, Leukotrienes and Essential Fatty Acids",

issn = "0952-3278",

publisher = "Churchill Livingstone",

number = "2",

}

TY - JOUR

T1 - Effect of pravastatin on fatty acid profile of low density lipoprotein in patients with hypercholesterolemia

AU - Hong, C. Y.

AU - Lin, S. J.

AU - Chang, M. S.

AU - Chiang, B. N.

AU - Shen, P. M.

AU - Shiao, M. S.

PY - 1993/2

Y1 - 1993/2

N2 - We gave pravastatin, an HMG-CoA reductase inhibitor, to 21 hypercholesterolemic patients for 12 weeks after they had been on dietary therapy for 12 weeks. In addition to inducing a significant reduction of total cholesterol and LDL-cholesterol, pravastatin significantly decreased the proportion of linoleic acid (18:2) and increased that of saturated (FA) (16:0 and 18:0) in the cholesterol ester of LDL. Linoleic acid was also reduced in the triglyceride of LDL. Besides, monounsaturated FA (16:1 and 18:1) were increased in the cholesterol ester, triglyceride and phospholipid of LDL, but the changes in monounsaturated FA were not statistically significant. The effect of pravastatin on the FA profile of LDL was similar to that of fibric acid derivatives. The mechanism as well as the clinical implication of these changes await further investigation.

AB - We gave pravastatin, an HMG-CoA reductase inhibitor, to 21 hypercholesterolemic patients for 12 weeks after they had been on dietary therapy for 12 weeks. In addition to inducing a significant reduction of total cholesterol and LDL-cholesterol, pravastatin significantly decreased the proportion of linoleic acid (18:2) and increased that of saturated (FA) (16:0 and 18:0) in the cholesterol ester of LDL. Linoleic acid was also reduced in the triglyceride of LDL. Besides, monounsaturated FA (16:1 and 18:1) were increased in the cholesterol ester, triglyceride and phospholipid of LDL, but the changes in monounsaturated FA were not statistically significant. The effect of pravastatin on the FA profile of LDL was similar to that of fibric acid derivatives. The mechanism as well as the clinical implication of these changes await further investigation.

UR - https://www.scopus.com/pages/publications/0027402845

U2 - 10.1016/0952-3278(93)90104-5

DO - 10.1016/0952-3278(93)90104-5

M3 - 文章

C2 - 8446653

AN - SCOPUS:0027402845

SN - 0952-3278

VL - 48

SP - 155

EP - 158

JO - Prostaglandins, Leukotrienes and Essential Fatty Acids

JF - Prostaglandins, Leukotrienes and Essential Fatty Acids

IS - 2

ER -

Effect of pravastatin on fatty acid profile of low density lipoprotein in patients with hypercholesterolemia

Abstract

Access to Document

Other files and links

Fingerprint

Cite this